BioCentury | May 17, 2019
Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

...drugs with precision dosing specifications, including those informed by modeling. He cited Gaucher disease drug Cerdelga...
BioCentury | Jan 27, 2018
Strategy

Growing up Genzyme

...from its existing relationships with hematologists, who prescribe the pharma’s Gaucher’s therapies Cerezyme imiglucerase and Cerdelga...
BioCentury | Jan 13, 2018
Strategy

Remapping growth

...Sibold, Sanofi Genzyme Hematologists are the primary prescribers of Sanofi’s marketed Gaucher’s disease therapies Cerdelga eliglustat tartrate...
BioCentury | Jul 28, 2017
Regulation

Ganging up in rare disease

...Vpriv. Sanofi declined to say whether it has started a required pediatric trial of Cerdelga eliglustat tartrate...
BioCentury | Jul 21, 2017
Company News

NICE final guidance recommends Sanofi's Cerdelga for Type I Gaucher's

...Last month, the U.K.'s NICE issued final guidance recommending the use of Cerdelga eliglustat from the...
...pay an expected cost of about £125,000 ($163,413). NICE said that Sanofi agreed to price Cerdelga...
...was uncertainty concerning the equivalence of Cerdelga vs. existing enzyme replacement therapy (ERT). But since Cerdelga...
BioCentury | Jan 11, 2016
Finance

Sowing season

...2011; Canada / South Korea in 2012) $412.1 (A) Genzyme Corp. / Sanofi (Euronext:SAN; NYSE:SNY) Cerdelga...
BioCentury | Jun 8, 2015
Product Development

Perennial pioneer

...and the largest development program in Gaucher's, something like 400 patients - we recently introduced Cerdelga...
BioCentury | May 21, 2015
Targets & Mechanisms

Intersection in marrow

...against the bone destruction in MM. She said the group is now working with Cerdelga eliglustat tartrate...
...I and Phase II, respectively, to treat Fabry's disease. Horwood added that neither Zavesca nor Cerdelga...
...storage disorders. The Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) markets the GCS inhibitor Cerdelga eliglustat tartrate...
BioCentury | Apr 6, 2015
Clinical News

Cerdelga eliglustat tartrate regulatory update

...Sanofi’s Genzyme Corp. unit said Japan approved Cerdelga eliglustat to treat Type I Gaucher’s disease in...
...U.S., the EU and Australia. Sanof i (Euronext:SAN; NYSE:SNY), Paris, France Product: Cerdelga eliglustat tartrate (formerly Genz-112638...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...U.S. (Japan in 2008; EU in 2011; Canada/South Korea in 2012) Genzyme Corp./Sanofi (Euronext:SAN; NYSE:SNY) Cerdelga...
Items per page:
1 - 10 of 60